Angiotensin (1-7) [Ang (1-7)] is a bioactive component of the renin angiotensin system. Ang (1-7) may interact with angiotensin type 1 (AT 1 ) or type 2 (AT 2 ) receptors and with Ang (1-7) -specific receptors. We examined the interactions between different doses of Ang (1-7) (1nM-1microM) and angiotensin II (Ang II) (10 and 100nM) on isolated rat portal vein. In endothelium-denuded portal vein rings, Ang (1-7) inhibited contractile effects induced by Ang II. The effects of Ang (1-7) were modified by indomethacin, N(G)-nitro-L-arginine methyl ester (L-NAME), (D-Ala 7 )-Angiotensin (1-7) (H-2888) and losartan. Our results suggest that on rat isolated portal vein rings without endothelium, Ang (1-7) reduces Ang II-induced contractions by acting mostly on Ang (1-7) specific receptors, and this effect is mediated by vasodilatatory prostaglandins. At high concentrations, Ang (1-7) effects are mediated by AT 1 -receptors, though to a lesser extent than by Ang (1-7) specific receptors.
Introduction
It has been shown that angiotensin II (Ang II) induces phasic contractions of endotheliumdenuded rat portal vein rings. This effect of Ang II has been demonstrated to be mediated predominantly by AT 1 -receptors, which represent about 75% of the Ang II specific binding sites at this level. [1] [2] [3] [4] [5] Angiotensin (1) (2) (3) (4) (5) (6) (7) [Ang (1) (2) (3) (4) (5) (6) (7) ] is a vasoactive angiotensin peptide that retains some of the actions ascribed to Ang II and counteracts others. There are many studies describing the effects of Ang (1-7) on cultured vascular smooth muscle cells (VSMCs), arterial rings and intact vessels. These Ang (1-7) effects are dose-dependent and are sometimes opposite to the effects of Ang II. In the micromolar range, Ang (1-7) effects are mediated by AT 1 , AT 2 or Ang (1-7) -specific receptors. [6] [7] [8] [9] [10] [11] [12] [13] Some authors have demonstrated that relaxant effects of Ang (1-7) at these concentrations are dependent on the presence of the intact endothelium. 10, [14] [15] [16] [17] In picomolar-nanomolar ranges, Ang (1-7) interacts for the most part with its specific receptors [18] [19] [20] [21] to produce vasodilatation. Ang (1-7) also has antiproliferative actions 22, 23 and the growth-inhibitory actions of Ang (1-7)
Paper on VSMCs are blocked by the D-Ala 7 -Ang (1-7) (on Ang (1-7) selective antagonist). 24 However, little is known about the roles of angiotensin peptides in regulating venous tone, or about the mechanisms involved.
We examined the effects of Ang (1-7) (1 nM to 1 µM) on endothelium-denuded rings of rat portal vein. Secondly, we studied the interactions between Ang (1-7) and Ang II (10 nM and 0.1 µM) as well as mechanisms and types of angiotensin receptors involved.
Methods
Male Wistar rats weighing 150-200g were decapitated and exsanguinated. The portal vein was rapidly removed and cleaned of connective tissue in Krebs-Henseleit solution (at 37 0 C) of the following composition (mM): NaCl 118, KCl 4.8, CaCl 2 2.5, MgSO 4 1.6, KH 2 PO 4 1.2, NaHCO 3 25, glucose 5.5; pH=7.4. Each portal vein was cut into rings, 2 mm wide and the endothelium was removed by gentle rubbing with a smooth softwood stick to avoid the implications of functional endothelium in the effects of angiotensin peptides. Individual rings were then mounted between hooks in 2 ml tissue chambers containing the Krebs-Henseleit solution at 37 0 C, bubbled continuously with 95% O 2 and 5% CO 2 . A resting tension of 1 g was applied to each ring, and then allowed to equilibrate for 90 minutes before the start of the experiment. The bathing medium was renewed every 15 minutes. Changes in isometric tension were displayed using a force transducer, a PC-LPM-16 multifunctional I/O board and NiDaqWin software (National Instruments). The study conformed to the Guide for the Care and Use of Laboratory Animals published in 1996 by the U.S. National Academy of Sciences and approved by the Ethics CoµMittee of the University of Medicine and Pharmacy "Gr. T.Popa" Iasi.
Experimental Design
The experiments were performed only in endothelium-denuded preparations with a stable baseline tension. After the equilibration period, the rat portal vein rings were initially stimulated with 40 mM KCl as a standard stimulus. The potassium solution had the same composition as the Krebs-Henseleit buffer used, except that an equimolar concentration of NaCl was replaced with KCl. Preparations with a response below 0.25 g were considered insufficiently viable and discarded. The amplitude of the 40 mM KClinduced contraction was considered as the control (100%) for further treatments.
The tested compounds were added to the organ bath at a maximal volume of 20 µl from stock solutions. To avoid tachyphylaxis, only a single response for an angiotensin peptide was allowed in each ring preparation. Different concentrations of Ang (1-7) (1 nM, 10 nM, 100 nM and 1 µM) were added 15 minutes before the addition of Ang II (10 and 100 nM). Appropriate controls were run at the same time in a different ring obtained from the same portal vein. In some experiments, N(G)-nitro-L-arginine methyl ester (L-NAME) (10 µM), indomethacin (10 µM), D-Ala 7 -Ang (1-7) (H-2888) (0.1 µM) or losartan (1 nM, 0.1 µM, 10 µM) were added 15 minutes before the addition of angiotensin peptides. At the end of the experiment, after the drugs had been washed out, carbachol (10 µM) was added in the plateau of a maximal response to phenylephrine (1 µM) in order to assess the presence or absence of functional endothelium.
Expression of Results and Statistical Analysis
The results are expressed as the percentage of the control contractions (KCl, 40 mM) (mean±SEM, n≥6). Rings from different animals were used to obtain the number of experiments. From each animal, a ring was used only once in experimental procedures. Statistical significance was tested using one-way analysis of variance (ANOVA), with Student-Newman-Keuls method (SigmaStat software, Jandel Corporation). Differences were considered statistically significant for p<0.05.
Drugs Used
Ang II, Ang (1-7), losartan, carbachol, phenylephrine were all obtained from Sigma. H-2888 was obtained from Bachem AG. All other compounds used were of analytical grade. Angiotensin peptides were stored frozen as aliquots, which were defrosted as required on the day of experiment. Dilutions of all drugs were made in Krebs-Henseleit solution.
Results
Contractions induced by 10 and 100 nM Ang II on denuded rat portal vein rings were 104.34±6.37% (n=12) and respectively, 121.43±5.75% (n=6), (p<0.05, as compared with the control contraction induced by K+ 40 mM) ( Figure 1 ).
Ang (1-7) in concentrations of 1 nM to 1 µM did not significantly contract rat portal vein rings as compared with vehicle (data not shown). (n=7), 67.42±5.68% (n=6), 34.96±3.21% (n=6) and 63.76±5.86% (n=6) respectively. 10 nM Ang II contractile effects were markedly inhibited by pretreatment with 10 nM, 0.1 µM and 1 µM Ang (1-7) (p<0.05 as compared with 10 nM Ang II-induced contractions); the powerful inhibitory effect was produced by 0.1 µM Ang (1-7).
The effects of inhibitors of nitric oxide (NO) synthase (N(G)-nitro-L-arginine methyl ester, L-NAME, 10 µM) and of cyclooxygenase (indomethacin, 10 µM on the actions of Ang (1-7) (1 nM to 1 µM) effects on 10 nM Ang II-induced contractions are presented in Figure 2 . In order to verify the contribution of the NO pathway on Ang (1-7) effects, 10 µM L-NAME was administrated 15 minutes before Ang (1-7). L-NAME slightly decreased inhibition of contractile effects of 10 nM Ang II by various concentrations of Ang (1-7) (92.36±5.17%, 69.83±4.19%, 40.86±4.05% and 67.40±4.12%). To determine the involvement of vasodilatatory prostaglandins (PG) on Ang (1-7) effects, 10 µM indomethacin was administrated 15 minutes before Ang (1-7). Indomethacin did not modify the effects of 1 nM Ang (1-7) (94.37±5.39%), In order to test the contribution of AT 1 -receptors to Ang (1-7) effects, we administered losartan, a nonspecific AT 1 -receptor blocker, before Ang 1-7) ]. The inhibitory effects of Ang (1-7) were more pronounced in the presence of 1 nM losartan than in the presence of 0.1 µM losartan; these differences were significant for 1 µM Ang (1-7) .
Co-administrations of 0.1 µM losartan with either 10 µM L-NAME or 10 µM indomethacin did not significantly modify the effects of 0.1 µM Ang (1-7) on 0.1 µM Ang II in the presence of 0.1 µM losartan, as compared with results obtained without L-NAME or indomethacin. When H-2888 (10 µM) was added to 0.1 µM losartan, Ang IIinduced contraction after pretreatment with Ang (1-7) was not significantly different (70.86±4.75%) as compared with Ang II-induced contraction in presence of losartan alone ( Figure 5 ).
Discussion
It has been demonstrated that Ang (1-7) can be synthesised in the vessel wall from either Ang I or Ang II. [25] [26] [27] Synthesis of Ang (1-7) is amplified by angiotensin-converting enzyme inhibitors (ACE-I). 28, 29 Ang (1-7) effects are dependent on concentration, the vascular bed investigated and the species studied. 11, 12, 30, 31 Moreover, it has been reported that the effects of Ang (1-7) are mediated by different types of receptors, including D-Ala 7 -Ang (1-7) (A-779)-sensitive, PD 123319sensitive and losartan-sensitive receptors.
Ang (1-7) can bind AT 1 -receptors on vessels 8 to produce vasoconstriction or activation of local kinin production. 32 Ang (1-7) downregulates AT 1receptors and decreases Ang II-binding at these receptors. [33] [34] [35] [36] [37] [38] Ang (1-7) also acts on AT 2 -receptors to induce synthesis of PG 6, 13 or NO. 32 On vessels and VSMC, Ang (1-7) -specific receptors mediate vasodilatory and antiproliferative effects of Ang (1-7) . 23, 24, 39, 40 Effects of Ang (1-7) on specific receptors can be mediated by synthesis/ release of NO and PG. 7, 13, 18, [41] [42] [43] [44] Some of the actions of Ang (1-7) are mediated by activation of kallikrein-kinin system. The vasorelaxant effects of Ang (1-7) via endothelial NO release is markedly attenuated by bradykinin (BK) B 2 receptor antagonists, while, on the other hand, Ang (1-7) intensifies BK-induced vasodilation. 15, 39, [45] [46] [47] In Wistar rats, Ang (1-7) increased the BK hypotensive effect; this action of Ang (1-7) was completely abolished by A-779 and increased by enalaprilat. 48 Ang (1-7) potentiated the action of bradykinin on its B 2 -receptor. 49 Ang (1-7) is a major substrate and an inhibitor for ACE. 39, 50 This might explain how Ang (1-7) retards the degradation of BK and suggests that Ang (1-7) acts as a local synergistic modulator of kinininduced vasodilation. 39 Thus, Ang (1-7) by acting on different angiotensin receptors, caused release of NO and vasodilatatory PGs, in part via activation of the vascular kallikreinkinin system.
Our results showed that Ang (1-7) (1 nM, 10 nM, 0.1 µM, 1 µM) did not significantly modify the tone of isolated rat portal vein rings without endothelium per se, but significantly reduced the contractions induced by 10 nM Ang II (Figure 1) . The maximal effect of the Ang (1-7) was observed at 100 nM.
To investigate the mechanisms involved in Ang (1-7) actions on rat portal vein smooth muscle, we blocked nitric oxide synthase (NOS) and vasodilatatory PG synthesis using L-NAME and indomethacin, respectively, administrated within 15 minutes before Ang (1-7) ( Figure 2 ). L-NAME has little effect on the actions of Ang (1-7) . These results are in contrast with previous reports, 30, 23 which may be explained by absence of endothelium. On the other hand, indomethacin strongly decreased the inhibitory effects of Ang (1-7) (0.1 and 1 µM) on 10 nM Ang II (Figure 3 ). Thus, in the absence of endothelium, Ang (1-7) may act via PG synthesis. These findings consistent with results obtained by other authors. 6, 7, 13, 51 To investigate the types of angiotensin receptors involved in Ang (1-7) actions on denuded rat portal vein rings, we used losartan and H-2888 administrated 15 minutes before Ang (1-7) ( Figure 3 ). Administration of the Ang (1-7) specific antagonist, H-2888, considerably (1-7) . Effects of 0.1 and 1 µM Ang (1-7) fluctuate with losartan doses, suggesting that at these concentrations Ang (1-7) could bind to AT 1 -receptors (Figure 4 ). On the other hand, our results show that partial blockade of AT 1receptors can amplify the effects of Ang (1-7).
Because 0.1 µM Ang (1-7) has powerful effects, we used this concentration to study the effects of co-administration of losartan with L-NAME, indomethacin and H-2888. Co-administration of losartan and H-2888 nearly completely reversed the inhibitory effects of Ang (1-7) on Ang IIinduced contractions ( Figure 5 ). These results suggests that, in the micromolar range, Ang (1-7) may act, in part, on AT 1 -receptors. However, co-administration of losartan and H-2888 did not completely reverse the effects of Ang (1-7) , which suggests contributions by other receptors.
Correlating the existence of Ang (1-7) synthesis pathways in the vascular wall with attenuation of Ang II-induced contractions by Ang (1-7),we can suggest that local formation of Ang (1-7) represents a local regulatory mechanism of either local or circulating renin-angiotensin systems (RAS) on vascular tone. On denuded rat portal vein, these actions of Ang (1-7) are present at doses higher than physiological. 52, 53 However, concentrations of Ang (1-7) increase during treatment with either ACE-I or AT 1 -receptor blockade, 37,53-55 our results show that losartan amplified the effects of Ang (1-7). Thus, this local regulator mechanism may become manifest when there is an augmentation of synthesis and/or actions of Ang (1-7), as during AT 1 -blockade or ACE-I treatment.
Conclusion
Ang (1-7) (1 nM to 1 µM) has no significant effects on the tone of endothelium-denuded rat portal vein rings by itself, but significantly reduces contractions induced by 10 nM Ang II (nor by 100 nM Ang II). These effects of Ang (1-7) are mediated mainly by its specific receptors and, to a lesser extent by AT 1 -receptors (for micromolar concentrations). Cyclooxygenase products play an important role in Ang (1-7) effects. 
